Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

This study tests tislelizumab (an immunotherapy drug) combined with chemotherapy given before surgery (neoadjuvant treatment) for people with locally advanced oral cancer (squamous cell carcinoma of the mouth). **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with locally advanced oral squamous cell carcinoma (stage III or IVb) - You have not yet received any systemic treatment (chemotherapy, immunotherapy, or targeted therapy) for this cancer - You have at least one measurable tumor - You are in good general health (ECOG 0–1) with adequate organ function **You may NOT be eligible if...** - You have had another cancer that was not fully cured more than 5 years ago - You have a history of active bleeding or clotting disorders - You have active autoimmune disease requiring systemic treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.